ESR1 and neoplasm: Firstly, our study shows that ER, PR, and HER2 are lost and gained in a considerable proportion of patients throughout tumor progression: loss of ER in five cases, gain of ER in two cases, loss of PR in seven cases, gain of PR in one case, loss of HER2 in two cases, and gain of HER2 in two cases.